Interaction Checker

Interaksi Gefitinib

Gefitinib (Iressa) memiliki 108 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 8 mayor, 100 moderat, 0 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (8)

  • Dekslansoprazolpenghambat pompa protonMayor

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (label Gefitinib, Interaksi obat)

  • Esomeprazolpenghambat pompa protonMayor

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (label Gefitinib, Interaksi obat)

  • Lansoprazolpenghambat pompa protonMayor

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (label Gefitinib, Interaksi obat)

  • Naproksen dan esomeprazolOAINSMayor

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (label Gefitinib, Interaksi obat)

  • Omeprazolpenghambat pompa protonMayor

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (label Gefitinib, Interaksi obat)

  • Omeprazol dan natrium bikarbonatpenghambat pompa protonMayor

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (label Gefitinib, Interaksi obat)

  • Pantoprazolpenghambat pompa protonMayor

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (label Gefitinib, Interaksi obat)

  • Rabeprazolpenghambat pompa protonMayor

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (label Gefitinib, Interaksi obat)

Interaksi moderat (100)

  • AmiodaronantiaritmiaModerat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • Amitriptilinantidepresan trisiklikModerat

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

  • Amoksapinantidepresan trisiklikModerat

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

  • Antasida (Tums, Maalox, Mylanta)Produk obat bebasModerat

    Drugs Affecting Gastric pH Drugs that elevate gastric pH (e.g., proton pump inhibitors, histamine H 2 -receptor antagonists, and antacids) may reduce plasma concentrations of gefitinib. (label Gefitinib, Interaksi obat)

  • Aprepitantpenghambat CYP3A4Moderat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • Armodafinilstimulan SSPModerat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • AtazanavirantiretroviralModerat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • Bosentanpenginduksi CYP3A4Moderat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • BupropionantidepresanModerat

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

  • DarunavirantiretroviralModerat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • Darunavir dan kobisistatantiretroviralModerat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • Deferasirokssuplemen zat besiModerat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • DeksametasonkortikosteroidModerat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • Desipraminantidepresan trisiklikModerat

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

  • DesvenlafaksinSNRIModerat

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

  • Diltiazempenghambat kanal kalsiumModerat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • Doksepinantidepresan trisiklikModerat

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

  • DronedaronantiaritmiaModerat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • DuloksetinSNRIModerat

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

  • EfavirenzantiretroviralModerat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • Efavirenz, lamivudin, dan tenofovirantiretroviralModerat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • Elvitegravir, kobisistat, emtrisitabin, dan tenofovirantiretroviralModerat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • Eritromisinantibiotik makrolidaModerat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • EsitalopramSSRIModerat

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

  • EslikarbazepinantikonvulsanModerat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • EtravirinantiretroviralModerat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • EverolimusimunosupresanModerat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • Famotidinpenghambat H2Moderat

    Drugs Affecting Gastric pH Drugs that elevate gastric pH (e.g., proton pump inhibitors, histamine H 2 -receptor antagonists, and antacids) may reduce plasma concentrations of gefitinib. (label Gefitinib, Interaksi obat)

  • Fenelzinpenghambat MAOModerat

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

  • FenitoinantikonvulsanModerat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • FenobarbitalbarbituratModerat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • Fentermin dan topiramatstimulan SSPModerat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • Flukonazolantijamur azolModerat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • FluoksetinSSRIModerat

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

  • FluvoksaminSSRIModerat

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

  • FosamprenavirantiretroviralModerat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • Fosaprepitantpenghambat CYP3A4Moderat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • FosfenitoinantikonvulsanModerat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • GriseofulvinantijamurModerat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • Ibuprofen dan famotidinOAINSModerat

    Drugs Affecting Gastric pH Drugs that elevate gastric pH (e.g., proton pump inhibitors, histamine H 2 -receptor antagonists, and antacids) may reduce plasma concentrations of gefitinib. (label Gefitinib, Interaksi obat)

  • Imatinibpenghambat CYP3A4Moderat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • Imipraminantidepresan trisiklikModerat

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

  • IsoniazidantibiotikModerat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • Itrakonazolantijamur azolModerat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • Ivakaftorpenghambat CYP3A4Moderat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • KarbamazepinantikonvulsanModerat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • Ketokonazolantijamur azolModerat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • Klaritromisinantibiotik makrolidaModerat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • KlobazambenzodiazepinModerat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • Klomipraminantidepresan trisiklikModerat

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

  • LenakapavirantiretroviralModerat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • LevomilnasipranSNRIModerat

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

  • Lopinavir dan ritonavirantiretroviralModerat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • Lorlatinibpenginduksi CYP3A4Moderat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • Mifepristonpenghambat CYP3A4Moderat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • Mirabegronagonis beta-adrenergikModerat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • MirtazapinantidepresanModerat

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

  • Mitapivatpenginduksi CYP3A4Moderat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • Mitotanpenginduksi CYP3A4Moderat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • Modafinilstimulan SSPModerat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • Nafsilinantibiotik penisilinModerat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • Naltrekson dan bupropionantagonis opioidModerat

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

  • Natrium bikarbonatantasidaModerat

    Drugs Affecting Gastric pH Drugs that elevate gastric pH (e.g., proton pump inhibitors, histamine H 2 -receptor antagonists, and antacids) may reduce plasma concentrations of gefitinib. (label Gefitinib, Interaksi obat)

  • NefazodonantidepresanModerat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • NevirapinantiretroviralModerat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • Nirmatrelvir dan ritonavirantivirusModerat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • Nizatidinpenghambat H2Moderat

    Drugs Affecting Gastric pH Drugs that elevate gastric pH (e.g., proton pump inhibitors, histamine H 2 -receptor antagonists, and antacids) may reduce plasma concentrations of gefitinib. (label Gefitinib, Interaksi obat)

  • Nortriptilinantidepresan trisiklikModerat

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

  • OkskarbazepinantikonvulsanModerat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • Olanzapin dan fluoksetinantipsikotikModerat

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

  • Palbosiklibpenghambat CYP3A4Moderat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • ParoksetinSSRIModerat

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

  • PerampanelantikonvulsanModerat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • Posakonazolantijamur azolModerat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • PrimidonantikonvulsanModerat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • Protriptilinantidepresan trisiklikModerat

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

  • Ranitidinpenghambat H2Moderat

    Drugs Affecting Gastric pH Drugs that elevate gastric pH (e.g., proton pump inhibitors, histamine H 2 -receptor antagonists, and antacids) may reduce plasma concentrations of gefitinib. (label Gefitinib, Interaksi obat)

  • Ranolazinobat yang memperpanjang interval QTModerat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • RifabutinantibiotikModerat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • RifampisinantibiotikModerat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • RifapentinantibiotikModerat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • RitonavirantiretroviralModerat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • SenobamatantikonvulsanModerat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • SertralinSSRIModerat

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

  • SiklosporinimunosupresanModerat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • Simetidinpenghambat H2Moderat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • SitalopramSSRIModerat

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

  • Suvoreksantsedatif-hipnotikModerat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • Suzetriginpenginduksi CYP3A4Moderat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • TikagrelorantiplateletModerat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • TopiramatantikonvulsanModerat

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (label Gefitinib, Interaksi obat)

  • Tranilsiprominpenghambat MAOModerat

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

  • TrazodonantidepresanModerat

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

  • Trimipraminantidepresan trisiklikModerat

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

  • VenlafaksinSNRIModerat

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

  • Verapamilpenghambat kanal kalsiumModerat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • VilazodonSSRIModerat

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

  • Vorikonazolantijamur azolModerat

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (label Gefitinib, Interaksi obat)

  • VortioksetinantidepresanModerat

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (label Gefitinib, Interaksi obat)

  • WarfarinantikoagulanModerat

    • Hemorrhage in patients taking warfarin: Monitor changes in prothrombin time or INR. (label Gefitinib, Interaksi obat)

Periksa Gefitinib terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.